Drug Profile
ALT 4037
Latest Information Update: 03 Feb 2017
Price :
$50
*
At a glance
- Originator Alteon
- Developer Synvista Therapeutics
- Class
- Mechanism of Action Advanced glycosylation end product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 02 Feb 2017 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route)
- 17 Dec 2003 Suspended - Preclinical for Diabetes mellitus in USA (unspecified route)
- 19 Dec 2001 Alteon has received a key US patent on Glucose Lowering Compounds